Abnormality of TOP2A expression and its gene copy number variations in neuroblastic tumors
10.3760/cma.j.issn.0529-5807.2016.11.002
- VernacularTitle:儿童神经母细胞源性肿瘤TOP2A蛋白表达及其基因拷贝数的变化
- Author:
Jiamin CHEN
1
;
Chunju ZHOU
;
Xiaoli MA
;
Dandan GUAN
;
Lingyun YANG
;
Pin YUE
;
Liping GONG
Author Information
1. 100069,首都医科大学病理学系
- Keywords:
Neuroblastoma;
DNA topoisomerases,type Ⅱ;
Immunohistochemistry;
In situ hybridization,fluorescence
- From:
Chinese Journal of Pathology
2016;45(11):748-754
- CountryChina
- Language:Chinese
-
Abstract:
Objective To detect TOP2A protein expression and gene copy number alterations, and to analyze related clinical and pathological implications in pediatric neuroblastic tumors ( NT ).Methods Immunohistochemistry was used to detect TOP2A protein expression.Fluorescence in situ hybridization (FISH) was used to detect numerical aberrations of TOP2A.Results TOP2A protein was expressed in 59.1%(52/88) of cases, which was associated with differentiation (P=0.006), Ki-67 index (P<0.01) and MKI (P=0.001).Twenty-eight cases (35.0%, 28/88) showed TOP2A gene amplification, which was correlated with the age (P<0.01), clinical stage (P=0.028), high risk group (P=0.001), Ki-67 index (P=0.040) and differentiation (P=0.014).Survival analysis showed that TOP2A expression was related to survival rate.Multivariate analyses showed that TOP2A expression was an independent predictor for poor prognosis (P=0.010).Conclusions More than half of the cases show TOP2A expression, which is more likely associated with NB, high Ki-67 index and high MKI.Cases with TOP2A expression have shorter survivals and poorer prognosis.TOP2A amplification is seen in 35% and likely occurs in patients older than 18 months and at advanced INSS stages (Ⅲ and Ⅳ).As a target of the anthracycline-based adjuvant drugs, TOP2A test can be used to select patient with NT for the therapy.
